MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

MDT

94.99

-0.35%↓

VEEV

292.58

+1.89%↑

A

140.97

+1.06%↑

HQY

90.94

-1.4%↓

TLRY

1.54

-8.33%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

3.47 3.58

Overview

Share price change

24h

Current

Min

3.36

Max

3.64

Key metrics

By Trading Economics

Income

-17M

-70M

Sales

547K

47M

Profit margin

-147.345

Employees

560

EBITDA

-17M

-66M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+38.58% upside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

415M

1.2B

Previous open

-0.11

Previous close

3.47

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 paź 2025, 21:10 UTC

Major Market Movers

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16 paź 2025, 19:03 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16 paź 2025, 17:58 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16 paź 2025, 17:12 UTC

Earnings

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16 paź 2025, 17:12 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16 paź 2025, 16:59 UTC

Acquisitions, Mergers, Takeovers

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16 paź 2025, 23:44 UTC

Market Talk

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16 paź 2025, 23:42 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16 paź 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

16 paź 2025, 22:15 UTC

Earnings

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16 paź 2025, 22:15 UTC

Earnings

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16 paź 2025, 22:15 UTC

Earnings

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16 paź 2025, 22:02 UTC

Market Talk

Global Equities Roundup: Market Talk

16 paź 2025, 22:02 UTC

Market Talk

Santos Drifts Into 'Oversold Territory' -- Market Talk

16 paź 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 paź 2025, 20:50 UTC

Market Talk
Earnings

Health Care Roundup: Market Talk

16 paź 2025, 20:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 paź 2025, 20:23 UTC

Market Talk

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16 paź 2025, 20:20 UTC

Earnings

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16 paź 2025, 20:08 UTC

Acquisitions, Mergers, Takeovers

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16 paź 2025, 19:37 UTC

Acquisitions, Mergers, Takeovers

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16 paź 2025, 19:26 UTC

Earnings

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 paź 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16 paź 2025, 19:23 UTC

Market Talk

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16 paź 2025, 19:23 UTC

Earnings

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 paź 2025, 18:35 UTC

Market Talk
Earnings

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16 paź 2025, 18:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 paź 2025, 18:31 UTC

Market Talk

Global Equities Roundup: Market Talk

16 paź 2025, 18:31 UTC

Market Talk

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16 paź 2025, 16:57 UTC

Market Talk

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

38.58% upside

12 Months Forecast

Average 4.67 USD  38.58%

High 5 USD

Low 4 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat